Japonicone A antagonizes the activity of TNF-α by directly targeting this cytokine and selectively disrupting its interaction with TNF receptor-1

Biochemical Pharmacology

Volumn 84, Issue 11, 2012, Pages 1482-1491

  Hu, Zhenlin ^a   Qin, Jiangjiang ^b   Zhang, Huahua ^c   Wang, Dan ^a   Hua, Yaping ^b   Ding, Jieping ^a   Shan, Lei ^a   Jin, Huizi ^b   Zhang, Junping ^a   Zhang, Weidong ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Department of Pharmacy   (China)

Author keywords

Antagonist; Inflammation; Japonicone A; Tumor necrosis factor receptor 1; Tumor necrosis factor

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; JAPONICONE A; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEPATITIS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CLEARANCE; DRUG CYTOTOXICITY; HOST RESISTANCE; IMMUNE RESPONSE; IN VITRO STUDY; LIVER INJURY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, INBRED BALB C; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURFACE PLASMON RESONANCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868375682     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.08.025     Document Type: Article

References (62)

1. B.B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword Nat Rev Immunol 3 2003 745 756
2. R.F. Schwabe, and D.A. Brenner Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways Am J Physiol Gastrointest Liver Physiol 290 2006 G583 G589
3. C.A. Bradham, J. Plumpe, M.P. Manns, D.A. Brenner, and C. Trautwein Mechanisms of hepatic toxicity. I. TNF-induced liver injury Am J Physiol 275 1998 G387 G392
4. Y. Yamada, and N. Fausto Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor Am J Pathol 152 1998 1577 1589
5. Y. Yamada, E.M. Webber, I. Kirillova, J.J. Peschon, and N. Fausto Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor Hepatology 28 1998 959 970
6. K.B. Elkon, C.C. Liu, J.G. Gall, J. Trevejo, M.W. Marino, and K.A. Abrahamsen Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors Proc Natl Acad Sci USA 94 1997 9814 9819
7. M. Pasparakis, L. Alexopoulou, V. Episkopou, and G. Kollias Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response J Exp Med 184 1996 1397 1411
8. M. Jacobs, A. Samarina, S. Grivennikov, T. Botha, N. Allie, and C. Fremond Reactivation of tuberculosis by tumor necrosis factor neutralization Eur Cytokine Netw 18 2007 5 13
9. T. Hehlgans, and K. Pfeffer The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games Immunology 115 2005 1 20
10. S. Bluml, C. Scheinecker, J.S. Smolen, and K. Redlich Targeting TNF receptors in rheumatoid arthritis Int Immunol 24 2012 275 281
11. E.Y. Kim, J.J. Priatel, S.J. Teh, and H.S. Teh TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo J Immunol 176 2006 1026 1035
12. E.Y. Kim, and H.S. Teh TNF type 2 receptor (p75) lowers the threshold of T cell activation J Immunol 167 2001 6812 6820
13. M. Grell, F.M. Becke, H. Wajant, D.N. Mannel, and P. Scheurich TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1 Eur J Immunol 28 1998 257 263
14. E. Esposito, and S. Cuzzocrea TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma Curr Med Chem 16 2009 3152 3167
15. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials J Am Med Assoc 295 2006 2275 2285
16. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155
17. J. Listing, A. Strangfeld, S. Kary, R. Rau, U. von Hinueber, and M. Stoyanova-Scholz Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 2005 3403 3412
18. R. Perez-Alvarez, C. Diaz-Lagares, F. Garcia-Hernandez, L. Lopez-Roses, P. Brito-Zeron, and M. Perez-de-Lis Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine (Baltimore) 90 2011 359 371
19. N.C. Boetticher, C.J. Peine, P. Kwo, G.A. Abrams, T. Patel, and B. Aqel A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis Gastroenterology 135 2008 1953 1960
20. T. Poynard, D. Thabut, A. Chryssostalis, J. Taieb, and V. Ratziu Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol 38 2003 518 520
21. F. Van Hauwermeiren, R.E. Vandenbroucke, and C. Libert Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1 Cytokine Growth Factor Rev 22 2011 311 319
22. H. Shibata, Y. Yoshioka, A. Ohkawa, K. Minowa, Y. Mukai, and Y. Abe Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist J Biol Chem 283 2008 998 1007
23. H. Shibata, Y. Yoshioka, A. Ohkawa, Y. Abe, T. Nomura, and Y. Mukai The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models Cytokine 44 2008 229 233
24. H. Shibata, Y. Yoshioka, Y. Abe, A. Ohkawa, T. Nomura, and K. Minowa The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF Biomaterials 30 2009 6638 6647
25. F.K. Chan, H.J. Chun, L. Zheng, R.M. Siegel, K.L. Bui, and M.J. Lenardo A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling Science 288 2000 2351 2354
26. D.W. Banner, A. D'Arcy, W. Janes, R. Gentz, H.J. Schoenfeld, and C. Broger Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation Cell 73 1993 431 445
27. Z.Q. Fu, R.W. Harrison, C. Reed, J. Wu, Y.N. Xue, and M.J. Chen Model complexes of tumor necrosis factor-alpha with receptors R1 and R2 Protein Eng 8 1995 1233 1241
28. M.M. He, A.S. Smith, J.D. Oslob, W.M. Flanagan, A.C. Braisted, and A. Whitty Small-molecule inhibition of TNF-alpha Science 310 2005 1022 1025
29. P.H. Carter, P.A. Scherle, J.K. Muckelbauer, M.E. Voss, R.Q. Liu, and L.A. Thompson Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha Proc Natl Acad Sci USA 98 2001 11879 11884
30. R. Murali, X. Cheng, A. Berezov, X. Du, A. Schon, and E. Freire Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107 Proc Natl Acad Sci USA 102 2005 10970 10975
31. A.T. Paul, V.M. Gohil, and K.K. Bhutani Modulating TNF-alpha signaling with natural products Drug Discov Today 11 2006 725 732
32. M.A. Palladino, F.R. Bahjat, E.A. Theodorakis, and L.L. Moldawer Anti-TNF-alpha therapies: the next generation Nat Rev Drug Discov 2 2003 736 746
33. J.J. Qin, H.Z. Jin, J.J. Fu, X.J. Hu, Y. Wang, and S.K. Yan Japonicones A-D, bioactive dimeric sesquiterpenes from Inula japonica Thunb Bioorg Med Chem Lett 19 2009 710 713
34. W. Qin, J. Feng, Y. Li, Z. Lin, and B. Shen A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides Mol Immunol 44 2007 2355 2361
35. 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors J Exp Med 162 1985 1099 1104
36. H. An, J. Hou, J. Zhou, W. Zhao, H. Xu, and Y. Zheng Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1 Nat Immunol 9 2008 542 550
37. G.R. Brown, D.L. Thiele, M. Silva, and B. Beutler Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium Gastroenterology 112 1997 1586 1594
38. A. Ullmann, F. Jacob, and J. Monod Characterization by in vitro complementation of a peptide corresponding to an operator-proximal segment of the beta-galactosidase structural gene of Escherichia coli J Mol Biol 24 1967 339 343
39. M.I. Kafrouni, G.R. Brown, and D.L. Thiele Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms J Immunol 167 2001 1566 1574
40. V. Baud, and M. Karin Signal transduction by tumor necrosis factor and its relatives Trends Cell Biol 11 2001 372 377
41. L.A. Madge, and J.S. Pober TNF signaling in vascular endothelial cells Exp Mol Pathol 70 2001 317 325
42. F. Mackay, H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55 J Exp Med 177 1993 1277 1286
43. S. Kondo, and D.N. Sauder Tumor necrosis factor (TNF) receptor type 1 (p55) is a main mediator for TNF-alpha-induced skin inflammation Eur J Immunol 27 1997 1713 1718
44. D. Wolf, R. Hallmann, G. Sass, M. Sixt, S. Kusters, and B. Fregien TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1-relevance for concanavalin A-induced hepatitis J Immunol 166 2001 1300 1307
45. I. Hishinuma, J. Nagakawa, K. Hirota, K. Miyamoto, K. Tsukidate, and T. Yamanaka Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice Hepatology 12 1990 1187 1191
46. M. Nagaki, A. Sugiyama, Y. Osawa, T. Naiki, S. Nakashima, and Y. Nozawa Lethal hepatic apoptosis mediated by tumor necrosis factor receptor, unlike Fas-mediated apoptosis, requires hepatocyte sensitization in mice J Hepatol 31 1999 997 1005
47. M.I. Kafrouni, G.R. Brown, and D.L. Thiele The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection J Leukoc Biol 74 2003 564 571
48. J.H. Choi, Y.N. Park, Y. Li, M.H. Jin, J. Lee, and Y. Lee Flowers of Inula japonica attenuate inflammatory responses Immune Netw 10 2010 145 152
49. Y.N. Park, Y.J. Lee, J.H. Choi, M. Jin, J.H. Yang, and Y. Li Alleviation of OVA-induced airway inflammation by flowers of Inula japonica in a murine model of asthma Biosci Biotechnol Biochem 75 2011 871 876
50. M. Heinrich, M. Robles, J.E. West, B.R. Ortiz de Montellano, and E. Rodriguez Ethnopharmacology of Mexican asteraceae (Compositae) Annu Rev Pharmacol Toxicol 38 1998 539 565
51. I.H. Hall, C.O. Starnes Jr., K.H. Lee, and T.G. Waddell Mode of action of sesquiterpene lactones as anti-inflammatory agents J Pharm Sci 69 1980 537 543
52. E. Koch, C.A. Klaas, P. Rungeler, V. Castro, G. Mora, and W. Vichnewski Inhibition of inflammatory cytokine production and lymphocyte proliferation by structurally different sesquiterpene lactones correlates with their effect on activation of NF-kappaB Biochem Pharmacol 62 2001 795 801
53. G.R. Schinella, R.M. Giner, M.C. Recio, P. Mordujovich de Buschiazzo, J.L. Rios, and S. Manez Anti-inflammatory effects of South American Tanacetum vulgare J Pharm Pharmacol 50 1998 1069 1074
54. O.S. Giordano, M.J. Pestchanker, E. Guerreiro, J.R. Saad, R.D. Enriz, and A.M. Rodriguez Structure-activity relationship in the gastric cytoprotective effect of several sesquiterpene lactones J Med Chem 35 1992 2452 2458
55. G.H. Wendel, A.O. Maria, F. Mohamed, S. Dominguez, L. Scardapane, and O.S. Giordano Effect of dehydroleucodine in experimental colitis in rats and mice Pharmacol Res 40 1999 339 344
56. B. Buchele, W. Zugmaier, O. Lunov, T. Syrovets, I. Merfort, and T. Simmet Surface plasmon resonance analysis of nuclear factor-kappaB protein interactions with the sesquiterpene lactone helenalin Anal Biochem 401 2010 30 37
57. A.J. Garcia-Pineres, V. Castro, G. Mora, T.J. Schmidt, E. Strunck, and H.L. Pahl Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones J Biol Chem 276 2001 39713 39720
58. G. Lyss, T.J. Schmidt, I. Merfort, and H.L. Pahl Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB Biol Chem 378 1997 951 961
59. S.P. Hehner, M. Heinrich, P.M. Bork, M. Vogt, F. Ratter, and V. Lehmann Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta J Biol Chem 273 1998 1288 1297
60. B.H. Kwok, B. Koh, M.I. Ndubuisi, M. Elofsson, and C.M. Crews The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase Chem Biol 8 2001 759 766
61. A. Ghantous, H. Gali-Muhtasib, H. Vuorela, N.A. Saliba, and N. Darwiche What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 15 2010 668 678
62. T.J. Schmidt, A.M. Nour, S.A. Khalid, M. Kaiser, and R. Brun Quantitative structure-antiprotozoal activity relationships of sesquiterpene lactones Molecules 14 2009 2062 2076